Cargando…

A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer

The standard treatment of nonmuscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intravesical therapy (IT), which comprises a direct instillation of a solution of Bacillus Calmette-Guérin vaccine or chemotherapy into the bladder. However, the recurrence rate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellat, Vanessa, Michel, Adam O., Thomas, Charlene, Stokol, Tracy, Choi, Benjamin B., Law, Benedict
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Translational Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983499/ https://www.ncbi.nlm.nih.gov/pubmed/35039320 http://dx.doi.org/10.1158/0008-5472.CAN-21-2897

Ejemplares similares

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection
por: Naya, Yoshio, et al.
Publicado: (2018)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
por: Bazarbashi, Shouki N., et al.
Publicado: (2016)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection
por: Bijalwan, Priyank, et al.
Publicado: (2017)

Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer
por: Lee, Hyun Hee, et al.
Publicado: (2017)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
por: Maruf, Mahir, et al.
Publicado: (2016)

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette–Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2021)

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients
por: Kowalski, Mark, et al.
Publicado: (2010)

Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder
por: Lim, So Dug, et al.
Publicado: (2015)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
por: Mohamed, Mohamed Bakr, et al.
Publicado: (2020)

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
por: Catto, James W. F., et al.
Publicado: (2021)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Randomized Trial
por: Gallagher, Kevin, et al.
Publicado: (2023)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
por: Serretta, Vincenzo, et al.
Publicado: (2015)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations
por: Wroclawski, Marcelo Langer, et al.
Publicado: (2019)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9hg8rd9nnmuv1lve2ffk4e86v